Korro Bio, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing a new class of genetic medicines based on RNA editing. The company uses its proprietary OPERA platform to harness the endogenous ADAR enzyme system to make precise single adenosine to inosine edits on RNA. This approach enables transient modification of protein function to treat both rare and prevalent diseases. The company's pipeline includes KRRO 121 for hyperammonemia, a GalNAc conjugated oligonucleotide designed to increase glutamine synthetase activity and improve ammonia clearance. Additional programs target alpha 1 antitrypsin deficiency via a GalNAc conjugated approach to correct the SERPINA1 transcript, activate AMPK gamma 1 for liver health and modulate TDP 43 to reduce protein aggregation in ALS.

The company has not yet commercialized any products and does not generate product revenue. Its current financial support comes from collaboration agreements such as the partnership with Novo Nordisk and from financing activities. The collaboration with Novo Nordisk provides potential funding for research and development of up to two programs in the cardiometabolic area, although the partnership is currently paused. The company also pursues non dilutive financing through government grants and partnerships with disease foundations. These sources support ongoing preclinical work and enable the advancement of lead candidates toward clinical trials.

Korro Bio, Inc. operates in the emerging field of RNA editing where it faces competition from companies such as AIRNA, Beam Therapeutics, Prime Medicine, ProQR, Tessera Therapeutics, Verve Therapeutics, Wave Life Sciences, YolTech Therapeutics, Edigene and Shape Therapeutics. The company differentiates itself through its proprietary OPERA platform which combines deep expertise in ADAR biology, oligonucleotide chemistry, machine learning optimization and validated delivery methods such as GalNAc conjugation. This integrated approach enables the design of highly specific oligonucleotides with efficient editing, low off target activity and favorable manufacturability. By leveraging the transient and reversible nature of ADAR mediated editing, Korro Bio aims to develop therapies that can be redosed and titrated, offering a potential advantage over permanent DNA editing approaches. These capabilities position the company to pursue both rare disorders and large patient populations in prevalent diseases. The OPERA platform uses high throughput cell based assays and machine learning models to rapidly iterate oligonucleotide designs and predict editing efficiency. By relying on established delivery technologies such as GalNAc conjugation, the company aims to reduce manufacturing complexity and improve scalability compared to viral vector or lipid nanoparticle approaches.

Although Korro Bio, Inc. has not yet marketed any therapies, its intended customers are patients suffering from conditions such as urea cycle disorders, hepatic encephalopathy, alpha 1 antitrypsin deficiency and amyotrophic lateral sclerosis. The company also hopes to serve health care providers and payers who will administer and reimburse its future treatments. Clinical trial investigators and medical centers represent additional partners in the development process. Preclinical studies have shown proof of concept for each program, demonstrating target engagement and favorable safety profiles in animal models. The company plans to initiate first in human trials for KRRO 121 in the second half of 2026 and for the alpha 1 antitrypsin deficiency program in 2027, subject to regulatory clearance.